These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12740921)

  • 1. Familial invasive and borderline ovarian tumors by proband status, age and histology.
    Hemminki K; Granström C
    Int J Cancer; 2003 Jul; 105(5):701-5. PubMed ID: 12740921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial clustering of ovarian and endometrial cancers.
    Hemminki K; Granström C
    Eur J Cancer; 2004 Jan; 40(1):90-5. PubMed ID: 14687794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population attributable fractions for ovarian cancer in Swedish women by morphological type.
    Granström C; Sundquist J; Hemminki K
    Br J Cancer; 2008 Jan; 98(1):199-205. PubMed ID: 18071361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attributable risks for familial breast cancer by proband status and morphology: a nationwide epidemiologic study from Sweden.
    Hemminki K; Granström C; Czene K
    Int J Cancer; 2002 Jul; 100(2):214-9. PubMed ID: 12115572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial breast carcinoma risks by morphology: a nationwide epidemiologic study from Sweden.
    Hemminki K; Granström C
    Cancer; 2002 Jun; 94(11):3063-70. PubMed ID: 12115398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial association of specific histologic types of ovarian malignancy with other malignancies.
    Lorenzo Bermejo J; Rawal R; Hemminki K
    Cancer; 2004 Apr; 100(7):1507-14. PubMed ID: 15042686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
    Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
    Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden.
    Hemminki K; Li X
    Int J Cancer; 2003 Feb; 103(4):525-30. PubMed ID: 12478670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of familial aggregation of ovarian and breast cancer in patients with ovarian cancer].
    Ichikawa Y; Nishida M; Sugita M; Arisawa Y; Satoh T; Oki A; Kohno K; Shigemitsu S; Tsunoda H; Kubo T
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Sep; 47(9):901-6. PubMed ID: 7594899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.
    Werness BA; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Dicioccio RA; Tsukada Y; Ponder BA; Piver MS
    Hum Pathol; 2000 Nov; 31(11):1420-4. PubMed ID: 11112219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second neoplasms after invasive and borderline ovarian cancer.
    Levi F; Randimbison L; Blanc-Moya R; La Vecchia C
    Eur J Cancer Prev; 2009 Jun; 18(3):216-9. PubMed ID: 19491608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and mortality in epithelial ovarian cancer by family history of any cancer.
    Hemminki K; Sundquist J; Brandt A
    Cancer; 2011 Sep; 117(17):3972-80. PubMed ID: 21365633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    Zheng G; Yu H; Kanerva A; Försti A; Sundquist K; Hemminki K
    PLoS One; 2018; 13(10):e0205000. PubMed ID: 30281663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial risk of cancer by site and histopathology.
    Hemminki K; Li X
    Int J Cancer; 2003 Jan; 103(1):105-9. PubMed ID: 12455061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma.
    Hemminki K; Aaltonen L; Li X
    Cancer; 2003 May; 97(10):2432-9. PubMed ID: 12733142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden.
    Kuokkanen M; Butzow R; Rasinperä H; Medrek K; Nilbert M; Malander S; Lubinski J; Järvelä I
    Int J Cancer; 2005 Oct; 117(1):90-4. PubMed ID: 15880573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of hereditary ovarian cancer (HOC) in Poland.
    Menkiszak J; Górski B; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Foszczyńska-Kłoda M; Fliciński J; Brzosko M; Rzepka-Górska I; Lubiński J
    Ginekol Pol; 2002 Sep; 73(9):733-9. PubMed ID: 12602271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian surface epithelial neoplasms in the pediatric population: incidence, histologic subtype, and natural history.
    Hazard FK; Longacre TA
    Am J Surg Pathol; 2013 Apr; 37(4):548-53. PubMed ID: 23388124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.